|
|
|
LifeScienceHistory.com - Check us out on Instagram
Take Your Next Career Step with Lundback
Maryland Life Science Industry Directory
Banner Advertising
Please note that we have a new site: LifeScienceHistory.com, "Where history is made daily" under development and
delayed by COVID-19, to be launched in 2023 replacing MarylandLifeScience.com. Regrettably, we are working with reduced
staffing and the current industry directory is no longer being maintained, but will be replaced with a new and improved
directory upon the launch of the new site. We apologize for the inconvenience.
Champions Oncology, Inc.
| | | Phone: | (410) 630-1313 | Fax: | (410) 630-1313 | Year Established: | 1985 | Ticker: | CSBR | Exchange: | NASDAQ | Main Contact: | Jordan Rubinson, MBA, CCO | | Other Contacts: | David Miller, MBA, VP, Finance Neal Goodwin, PhD, VP, R&D Angela M. Davies, MD, FRCP, CMO Joel Ackerman, CEO Ronnie Morris, MD, President
| | Company Description | Champions Oncology (formerly Champions Biotechnology) is engaged in the development of advanced technology solutions and services to personalize the development and use of oncology drugs. The company’s Champions TumorGraft® technology platform is a novel approach to personalizing cancer care based upon the implantation of primary human tumors in immune-deficient mice followed by propagation of the resulting engraftments, or patient-derived xenograft (PDX) models, in a manner that preserves the biological characteristics of the original human tumor in order to determine the efficacy of a treatment regimen. The company uses this technology in conjunction with related services to offer solutions for two customer groups: Personalized Oncology Solutions, in which results help guide the development of personalized treatment plans, and Translational Oncology Solutions, in which pharmaceutical and biotechnology companies seeking personalized approaches to drug development can lower the cost and increase the speed of developing new drugs. Champions TumorGraft PDX models are procured through agreements with a number of institutions in the U.S. and overseas as well as through the company’s Personalized Oncology Solutions business. | |
|
|
|
|
|